Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Eli Lilly (NY: LLY )

748.01 -1.91 (-0.25%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
99 100 Next >
7 A-Rated Biotech Stocks Worth Betting on in June
A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation. 
Via InvestorPlace
3 Stocks to Sell as Ozempic Surges in Popularity
GLP-1s are a weight-loss breakthrough, but these three stocks to sell have a lot to lose from their rapid rise in popularity. 
Via InvestorPlace
Wegovy's Precarious Position: 3 Drugs Most Likely to Dethrone Novo Nordisk's Blockbuster Obesity Drug
Novo Nordisk's competition in the obesity drug market is heating up. 
Via The Motley Fool
Weight Loss Drugs: Are They Really Magic?
Talking about weight and weight loss with Johann Hari, an Ozempic user and the author of "Magic Pill: The Extraordinary Benefits and Disturbing Risks of the New Weight-Loss Drugs." 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Eli Lilly and Co Stock: A Deep Dive Into Analyst Perspectives (17 Ratings)
Via Benzinga
JPMorgan's $500M Venture Capital Fund Bets Big On Weight-Loss Drugs: 'They're All The Rage'
JPMorgan's $500M venture capital fund dives into weight-loss craze, eyeing potential market upheaval in pharmaceuticals. 
Via Benzinga
3 Stocks to Buy if You Want to Turn Your $1,000 into $10,000 Within 2 Years
One of the best ways to spot winning stocks to buy is by spotting hot trends, such as artificial intelligence and obesity. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Stocks to Buy as Ozempic Surges in Popularity
Ozempic has surged in popularity in recent years, but the best may be to come as innovators look to launch new drugs to meet hot demand. 
Via InvestorPlace
Want to Get Richer? 2 Top Stocks to Buy Now and Hold Forever.
These proven wealth builders have what it takes to deliver solid gains long-term. 
Via The Motley Fool
Down 57%, Is AbCellera Biologics a Buy on the Dip?
Wall Street analysts say this drug developer can more than double your money. 
Via The Motley Fool
4 Best Stocks to Buy and 3 Best Stocks to Sell: June 2024
Consider making moves in these securities, each of which has news that is impacting their share price either positively or negatively. 
Via InvestorPlace
Humans Clamor For Weight Loss Drugs, But The Next Users Could Be... Pets?
Could GLP-1 drugs for weight loss in pets be the next big thing? Success of Novo Nordisk and Eli Lilly in human market could pave the way. 
Via Benzinga
3 Stocks Quietly Preparing for a 10X Surge: June Edition
There are plenty of 10x stocks with the potential to surge 10x over. We’ve already seen in happen with Apple, Netflix, Microsoft and Nvidia. 
Via InvestorPlace
A Life Expansion Revolution Is Coming: 3 Stocks That Could Lead the Charge
The integration of AI and healthcare is well underway. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
7 Trending Stocks With Momentum on Their Side
Trending stocks offer an opportunity to ride momentum higher and create quick returns for daring investors. 
Via InvestorPlace
3 Must-Buy Stocks Before the Third Quarter
Pounce on these three must buy-stocks before the third quarter starts, and take home solid gains as they soar on an improved economy. 
Via InvestorPlace
Is Eli Lilly the Best Pharmaceutical Stock for You?
Eli Lilly is serving a market that may reach $100 billion. 
Via The Motley Fool
Jim Cramer Sees Eli Lilly As More Than A 'One-Trick Pony' After FDA Advisors Back Its Alzheimer's Drug: 'It's Ultimately Headed To A Trillion Dollar Valuation'
Jim Cramer has expressed his confidence in Eli Lilly and Co, citing the company's diverse drug portfolio and the recent endorsement of its Alzheimer's treatment by FDA advisors. 
Via Benzinga
Exposures Product Safety
Eli Lilly Has Likely Blockbuster Drug, Elevated To Stock Spotlight: Joins These Names Just Added To IBD's Top Screens
Eli Lilly hit another all-time high Tuesday. It's seeing gains in large part because it's a leader in drugs to treat obesity and diabetes 
Via Investor's Business Daily
Eli Lilly's Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst
Eli Lilly's donanemab for Alzheimer's disease garners positive FDA committee verdict, prompting analyst's bullish outlook amid comparisons to Biogen's Leqembi. 
Via Benzinga
Exposures Product Safety
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win
An FDA panel unanimously backed Eli Lilly's Alzheimer's drug, but shares of Lilly and its rivals fell Tuesday. 
Via Investor's Business Daily
Exposures Product Safety
Why Are Stocks Down Today?
Stocks are down today and investors seeking out the answers to why that's the case will want to stick around for our Tuesday coverage. 
Via InvestorPlace
Eli Lilly Stock Hits New 52-Week High as FDA Panel Recommends Alzheimer’s Drug
Eli Lilly stock is up on Tuesday as investors in LLY celebrate an FDA panel putting its support behind the company's Alzheimer's drug. 
Via InvestorPlace
Exposures Product Safety
Top 4 Health Care Stocks That May Keep You Up At Night This Month
Via Benzinga
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
EQNX::TICKER_START (NASDAQ:TLSA),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:BIIB),(NASDAQ:TGTX) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
Why Is Eli Lilly Stock Trading Higher Premarket Tuesday?
Shares of Eli Lilly surged as an FDA advisory committee endorsed donanemab, an Alzheimer's treatment shown to significantly impact early-stage patients. The drug's benefits outstripped risks, setting... 
Via Benzinga
Exposures Product Safety
Eli Lilly Hits an All-Time High: Is the Soaring Pharma Stock Still a Buy?
The world's biggest healthcare company might become even larger. 
Via The Motley Fool
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
From FN Media Group LLC
Via GlobeNewswire
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.